🏛️ Verified NIH Record • Updated 2026-08-19

A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement (NCT07615270)

A Pilot Study of CAEL-101/Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement

🟡 Not Yet Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Stanford University

🩺 Plain-English Summary (8th-Grade Level)

This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.

Who can join: Review the eligibility criteria below.

Location: Stanford University — Palo Alto, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

  • Stanford University — Palo Alto, California

📞 Contact the Study Coordinator

Phone: (650) 723-0501

Email: mgupta4@stanford.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in AL Amyloidosis

Explore by condition: All AL Amyloidosis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗